Expert consensus on management of metabolic diseases in Chinese liver transplant recipients (2015 edition)

Liver transplant recipients are at high risk of metabolic diseases, which are closely associated with immunosuppressive regimens, cardiovascular diseases, renal dysfunction and infection, having significant influence on longterm survival of recipients. The expert consensus on management of metabolic diseases in Chinese liver transplant recipients (2015 edition) is composed by the Chinese College of Transplant Doctors, Section of Organ Transplantation, Chinese Society of Surgery, Section of Liver Transplantation, Chinese Society of Organ Transplantation, aimed at giving advices on the prophylaxis and treatment of metabolic diseases in the Chinese liver transplant recipients, and also improving longterm survival of recipients. Metabolic diseases are characterized by obesity, hyperglycemia, hypertension and hyperlipidemia. Management of metabolic diseases should be based on change of diet and lifestyle modification and combined with adjustment of immunosuppressive regimen and medical therapy. It is advised to reduce certain immunosuppressant that may contribute to metabolic disease on the premise of normal graft function, and the combined regimen of mycophenolate mofetil with no steroid and minimized calcineurin inhibitors is considered to be beneficial.